Clinical Trial Update: PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer [NA]

View source ↗

Summary

Completed clinical trial evaluating PET imaging with 89Zr-DFO-Trastuzumab in esophagogastric cancer; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Cancer

Drugs mentioned

• 89Zr-DFO-Trastuzumab (trastuzumab (radiolabeled with zirconium-89 via DFO chelator))

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophagogastric Cancer | NA | Status: COMPLETED | Results posted: 2024-12-10